Long-Term renal and cardiovascular outcomes in antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 6, 2012, Pages 989-1002

  Rahman, Mahboob ^a   Ford, Charles E ^a   Cutler, Jeffrey A ^a   Davis, Barry R ^a   Piller, Linda B ^a   Whelton, Paul K ^a   Wright, Jackson T ^a   Barzilay, Joshua I ^a   Brown, Clinton D ^a   Colon, Pedro J ^a   Fine, Lawrence J ^a   Grimm, Richard H ^a   Gupta, Alok K ^a   Baimbridge, Charles ^a   Julian Haywood, L ^a   Henriquez, Mario A ^a   Ilamaythi, Ekambaram ^a   Oparil, Suzanne ^a   Preston, Richard ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; LISINOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 84862213110     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07800811     Document Type: Article

References (38)

1. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065, 2003
3. Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P: Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49: 1778-1782, 1996
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEngl J Med 329: 1456-1462, 1993
5. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group: Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542-549, 2003
6. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group: Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48: 739-751, 2006
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
8. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165: 936-946, 2005
9. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group: Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 144: 172-180, 2006
10. Griffin KA, Hacioglu R, Abu-Amarah I, Loutzenhiser R, Williamson GA, Bidani AK: Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation. Am J Physiol Renal Physiol 286: F1136-F1143, 2004
11. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM; ALLHAT Research Group: Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9: 342-360, 1996
12. GrimmRHJr, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Eckfeldt J, Hawkins CM, Perry HM Jr, Proschan M; ALLHAT Collaborative Research Group: Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 37: 19-27, 2001
13. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283: 1967-1975, 2000
14. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354: 2473-2483, 2006
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
16. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, Steffes MW, Eggers PW, Coresh J, Levey AS: Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 56: 486-495, 2010
17. World Health Organization: International Classification of Diseases Two-Way Translator for the Ninth and Tenth Revisions, Geneva, Switzerland, World Health Organization, 1997
18. Holmes S: A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65-70, 1979
19. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group: The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 164: 969-976, 2004
20. Glassock RJ, Winearls C: Ageing and the glomerular filtration rate: Truths and consequences. Trans Am Clin Climatol Assoc 120: 419-428, 2009
21. Glassock RJ, Winearls C: An epidemic of chronic kidney disease: Fact or fiction? Nephrol Dial Transplant 23: 1117-1121, 2008
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
23. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, Neal B, Macmahon S, Chalmers J: Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS study. J Am Soc Nephrol 18: 2766-2772, 2007
24. Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E: Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. AmHeart J 155: 791-805, 2008
25. Segall L, Oprisiu R, Fournier A, Covic A: Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: A review of controlled trials. J Nephrol 21: 374-383, 2008
26. Galil AG, Pinheiro HS, Chaoubah A, Costa DM, Bastos MG: Chronic kidney disease increases cardiovascular unfavourable outcomes in outpatients with heart failure. BMC Nephrol 10: 31, 2009
27. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G; Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
28. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension StudyGroup: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
29. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 142: 342-351, 2005
30. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl JMed 363: 918-929, 2010
31. Loutzenhiser RD, Epstein M, Fischetti F, Horton C: Effects of amlodipine on renal hemodynamics. Am J Cardiol 64: 122I-127I, discussion 127I-128I, 1989
32. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
33. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
34. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int 80: 17-28, 2011
35. Segura J, Ruilope LM: Should diuretics always be included as initial antihypertensive management in early-stage CKD? Curr Opin Nephrol Hypertens 18: 392-396, 2009
36. National Kidney Foundation: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Guideline 7: Pharmacological therapy: Use of antihypertensive agents in CKD. Am J Kidney Dis 43[Suppl 1]: S1-S290, 2004
37. Reungjui S, Hu H, Mu W, Roncal CA, Croker BP, Patel JM, Nakagawa T, Srinivas T, Byer K, Simoni J, Wesson D, Sitprija V, Johnson RJ: Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int 72: 1483-1492, 2007
38. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The chronic renal insufficiency cohort (CRIC) study: Design and methods. J Am Soc Nephrol 14[Suppl 2]: S148-S153, 2003